CALCIUM D3-ratiopharm Forte effervescent tablets, 40 pcs

Instructions for use for CALCIUM D3-ratiopharm Forte effervescent tablets, 40 pcs

Detailed instructions for CALCIUM D3-ratiopharm Forte effervescent tablets, 40 pcs

Field of use

• The medicine is a calcium vitamin D3 preparation.
• It is used at
  • proven calcium and vitamin D3 deficiency as well as for the supportive treatment of osteoporosis.

Active ingredients / ingredients / ingredients

3000 mg calcium carbonate
1200 mg calcium ion
0.02 mg Colecalciferol
800 Ie Colecalciferol
alpha-tocopherol auxiliary material (+)
Ventracic acid auxiliary substances (+)
Citronic acid, water -free auxiliary material (+)
Maltodextrin auxiliary substance (+)
Sodium ascorbat auxiliary substance (+)
Sodium carbonate auxiliary substance (+)
Sodium cyclamat auxiliary substance (+)
Sodium hydrogen carbonate auxiliary material (+)
Saccharin, sodium salt auxiliary material (+)
1.54 mg sucrose auxiliary material (+)
Silicium dioxide, high disperser auxiliary substance (+)
Triglyceride, medium -chain auxiliary material (+)
Strength, modified auxiliary substances (+)
104 mg total sodium ion hedge material (+)
Lemon aroma hedge material (+)
Citron oil auxiliary material (+)
Mannitol Hilfoff (+)
Sorbitol auxiliary substance (+)
Dextrin auxiliary substance (+)
D-Glucono-1.5-lacton Hedge substance (+)
Arab rubber auxiliary substance (+)

Contradictions

• The medicine must not be used,
  • if you are allergic to calcium carbonate, Colecalciferol (vitamin D3) or one of the other components of this medicine.
  • with increased calcium content of the blood (hypercalcemia).
  • with increased calcium excretion in the urine (hypercalcuria).
  • with kidney limestone.
  • for tissue calcification of the kidney (nephrocalcinosis).
  • with limited kidney function (renal failure).
  • if the parathyroid gland is overwhelmed, which is usually based on an ancillary thyroid adenoma with increased parathormone release (primary hyperparathyroidism).
  • with vitamin D overdosing.
  • with multiplem bone market tumor (myeloma).
  • for daughter tumors in the bone (bone metastases).
  • when the limbs (immobilization) is immobilized.

dosage

• Always apply this medicine as described or exactly after the agreement made with your doctor or pharmacist. Ask your doctor or pharmacist if you are not sure.
• Unless otherwise prescribed by the doctor, the recommended dose is
  • Adults apply 1 effervescent tablet once a day (corresponding to 1200 mg calcium and 800 i.e. vitamin D3).

• Duration of the application
  • The application should take place in the long term.
  • Talk to your doctor how long you should apply the preparation.
  • Please speak to your doctor or pharmacist if you have the impression that the effect is too strong or too weak.

• If you have used a larger amount than you should
  • Overdosing can lead to nausea, vomiting, a pathological feeling of thirst, increased urine formation or constipation. If you suspect overdose, please inform your doctor immediately. This may take the necessary measures.

• If you have forgotten the application
  • Do not apply twice the amount if you have forgotten the previous application, but stay with your application rhythm.

• If you have any further questions about the application of this medicine, please contact your doctor or pharmacist.

Taking

• The effervescent tablet is dissolved in a glass of water and drunk immediately.
• You canen use the medicine for eating or between meals.

Patient information

• Warnings and Precautions
  • Please speak to your doctor or pharmacist before using the preparation.
  • Before ingestion, calcium and alkali absorption from other sources (e.g. food, enriched food or other medicines) should be observed. If high doses are given on calcium together with alkaline agents (such as carbonates), this can lead to a milk alkali syndrome (burnett syndrome). The milk alkali syndrome is a calcium metabolism disorder with an increase in the blood-calcium level. It can be triggered by absorbing very large amounts of milk and/or calcium carbonate from other sources or by excessive use of antacids (agent against stomach acidification). This can lead to side effects such as an increase in blood calcium level (hypercalcalcemia), metabolic alkalosis (due to the metabolism increase in blood-pH value), kidney failure and soft tissue calcification. Therefore, regular medical monitoring of the calcium levels in the blood is required.
  • During long-term treatment, the blood calcium level should be checked and the kidney function should be monitored by measuring the serum creatinine values. Monitoring is particularly important in older patients and in patients who receive cardiac glycosides and diuretics as accompanying medication. This also applies to patients with a pronounced tendency to form stone formation. If a calcium level that is too high in the blood (hypercalcemia) or signs of kidney dysfunction, the dose must be reduced or the therapy can be canceled.
  • Vitamin D may only be used carefully in patients with kidney dysfunction and under monitoring the calcium and phosphate levels. The risk of calcification of the soft tissues must be taken into account. Vitamin D in the form of Colecalciferol is not used by patients with severe kidney dysfunction. Therefore, these patients should receive other vitamin D preparations.
  • Additional intake of calcium and vitamin D may only be carried out under medical control, including a weekly review of the blood and urine calcium level.
  • In patients who suffer from sarcoidosis, the preparation should only be used with caution, since the risk of increased conversion of vitamin D into its active form insists. The calcium levels in the blood and urine should be monitored in these patients.
  • Certain tumors such as lung cancer (bronchial carcinoma), breast cancer (breast cancer), kidney cancer (hypernephrom) and blood cancer (plasma cytoma) can cause increased calcium level in the blood. The medicine should be used with caution in these patients. The calcium levels in the blood and urine should be monitored.

• Wateriness and ability to operate machines
  • There is no data on the influence of this drug on the traffic or operating machines. However, an influence is unlikely.

Pregnancy

• Pregnancy
  • During pregnancy, the daily dose should not exceed 1500 mg of calcium and 600 i.E. vitamin D3. This medicine should not be used during pregnancy and lactation due to the high dosage of vitamin D.
  • In pregnancy, an overdose must be avoided because, for a long time, hypercalcaemia in the child can lead to physical and mental developmental disorders, supravalvular aortic stenosis and non-inflammatory retinal diseases. However, there are also several case reports, which show that mothers suffered from reduced or lack of production of parathormone after taking very high vitamin doses. There is no evidence that vitamin D in therapeutic doses in humans act teratogenic.
• Breastfeeding
  • Calcium and vitamin D3 pass into breast milk. This should be noted if the child receives additional gifts of vitamin D. This preparation should not be used during breastfeeding due to the high dosage of vitamin D during breastfeeding will.

Hints